Brief, Intensive Lifestyle and Drug Treatment Improves Type 2 Diabetes

A short course of intensive lifestyle and drug therapy achieves on-treatment normoglycemia and promotes sustained weight loss.
A short course of intensive lifestyle and drug therapy achieves on-treatment normoglycemia and promotes sustained weight loss.

(HealthDay News) — Intensive lifestyle and drug therapy is associated with achievement of normoglycemia and sustained weight loss in patients with type 2 diabetes, according to a study published online in the Journal of Clinical Endocrinology & Metabolism.

Natalia McInnes, MD, from McMaster University in Hamilton, Canada, and colleagues randomly allocated 83 participants with type 2 diabetes to an 8-week intensive metabolic intervention, a 16-week intensive metabolic intervention, or standard diabetes care. Weight loss and normoglycemia were targeted with lifestyle approaches and treatment with metformin, acarbose, and insulin glargine during the intensive intervention period; diabetes drugs were then discontinued.

The researchers found that 50.0% and 3.6% of the 8-week intervention group and controls achieved normoglycemia on therapy at 8 weeks (relative risk, 14.0; 95% confidence interval [CI], 1.97 to 99.38); these percentages were 70.4% and 3.6% in the 16-week and control groups, respectively, at 16 weeks (relative risk, 19.7; 95% CI, 2.83 to 137.13). Overall, 21.4% of the 8-week group and 10.7% of controls and 40.7% of the 16-week group vs 14.3% of controls met hemoglobin A1c criteria for complete or partial diabetes remission at 12 weeks after completion of the intervention (relative risks, 2.00 [95% CI, 0.55 to 7.22] and 2.85 [95% CI, 1.03 to 7.87], respectively).

"A short course of intensive lifestyle and drug therapy achieves on-treatment normoglycemia and promotes sustained weight loss," the authors write.

Reference

  1. McInnes N, Smith A, Otto R, et al. Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. J Clin Endocrinol Metab. 15 March 2017. doi.org/10.1210/jc.2016-3373
You must be a registered member of Renal and Urology News to post a comment.

Newsletter Signup